GBT
PACB icon

Grove Bank & Trust’s Pacific Biosciences PACB Stock Holding History

Grove Bank & Trust’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-233
Closed -$1.95K – 671
2023
Q3 		$1.95K Buy
+233
New +$2.66K ﹤0.01% 650

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Grove Bank & Trust's PACB Position: Q4 2023 in Review

Grove Bank & Trust sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 233 shares — an estimated $1.95K sold.

Grove Bank & Trust first reported a position in PACB in Q3 2023 and held it in 1 quarter. The position peaked at $1.95K in Q3 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

  • Grove Bank & Trust reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
  • Grove Bank & Trust sold 233 Pacific Biosciences shares in Q4 2023, an estimated $1.95K.
  • Grove Bank & Trust first reported a position in Pacific Biosciences in Q3 2023 and held it in 1 quarter.
  • Grove Bank & Trust's Pacific Biosciences position peaked at $1.95K in Q3 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.